The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1
Open accessAbstract
In the present study, we showed that Chinese hamster ovary (CHO) cells transfected with human central cannabinoid receptor (CB1) exhibit high constitutive activity at both levels of mitogen-activated protein kinase (MAPK) and adenylyl cyclase. These activities could be blocked by the CB1-selective ligand, SR 141716A, that functions as an inverse agonist. Moreover, binding studies showed that guanine nucleotides decreased the binding of the agonist CP-55,940, an effect usually observed with agonists, whereas it enhanced the binding of SR 141716A, a property of inverse agonists. Unexpectedly, we found that CB1-mediated effects of SR 141716A included inhibition of MAPK activation by pertussis toxin-sensitive receptor-tyrosine kinase such as insulin or insulin-like growth factor 1 receptors but not by pertussis toxin-insensitive receptor-tyrosine kinase such as the fibroblast growth factor receptor. We also observed similar results when cells were stimulated with Mas-7, a mastoparan analog, that directly activates the Gi protein. Furthermore, SR 141716A inhibited guanosine 5'-0-(thiotriphosphate) uptake induced by CP-55,940 or Mas-7 in CHO-CB1 cell membranes. This indicates that, in addition to the inhibition of autoactivated CB1, SR 141716A can deliver a biological signal that blocks the Gi protein and consequently abrogates most of the Gi-mediated responses. By contrast, SR 141716A had no effect on MAPK activation by insulin or IGF1 in CHO cells lacking CB1 receptors, ruling out the possibility of a direct interaction of SR 141716A with the Gi protein. This supports the notion that the Gi protein may act as a negative intracellular signaling cross-talk molecule. From these original results, which considerably enlarge the biological properties of the inverse agonist, we propose a novel model for receptor/ligand interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Self-citationGaliègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., Bouaboula, M., Shire, D., LE Fur, G., & Casellas, P. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.tb20780.x · Cited by 1,749
Self-citationRole of transactivation of the EGF receptor in signalling by G-protein-coupled receptors
Daub, H., Ulrich Weiss, F., Wallasch, C., & Ullrich, A. (1996) · Nature · doi:10.1038/379557a0 · Cited by 1,476
Samama, P., Cotecchia, S., Costa, T., & Lefkowitz, R. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53442-6 · Cited by 1,257
The MAP kinase cascade is essential for diverse signal transduction pathways
Nishida, E., & Gotoh, Y. (1993) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(93)90019-j · Cited by 1,076
Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas
Parma, J., Duprez, L., Sande, J. V., Cochaux, P., Gervy, C., Mockel, J., Dumont, J., & Vassart, G. (1993) · Nature · doi:10.1038/365649a0 · Cited by 918
Cited by
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Self-citationThe Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“However, SR141716 and AM251 are inverse agonists (Gifford and Ashby, 1996; Bouaboula et al., 1997), which may be an alternative mechanism by which they reduce food intake.”
BackgroundLeptin-regulated endocannabinoids are involved in maintaining food intake
Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., et al. (2001) · Nature · doi:10.1038/35071088 · Cited by 1,559
G Protein-Coupled Receptor Allosterism and Complexing
Christopoulos, A., & Kenakin, T. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.323 · Cited by 931
The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0009 · Cited by 865
Cannabinoid receptors and pain
Pertwee, R. G. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00031-9 · Cited by 741
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1188 · Cited by 703
Bensaid, M., Gary-Bobo, M., Esclangon, A., Maffrand, J. P., Le Fur, G., Oury-Donat, F., & Soubrié, P. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.4.908 · Cited by 593
Self-citationCannabinoid receptors and their ligands
Pertwee, R. G., & Ross, R. A. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0341 · Cited by 561
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis
Teixeira-Clerc, F., Julien, B., Grenard, P., Van Nhieu, J. T., Deveaux, V., Li, L., Serriere-Lanneau, V., Ledent, C., Mallat, A., & Lotersztajn, S. (2006) · Nature Medicine · doi:10.1038/nm1421 · Cited by 528
CANNABINOID RECEPTORS AS THERAPEUTIC TARGETS
Mackie, K. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141254 · Cited by 505
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors
Pertwee, R. G. (2005) · Life Sciences · doi:10.1016/j.lfs.2004.10.025 · Cited by 444
Principles: Receptor theory in pharmacology
Kenakin, T. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.02.012 · Cited by 412
THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY
RODRÍGUEZ de FONSECA, F., DEL ARCO, I., BERMUDEZ-SILVA, F. J., BILBAO, A., CIPPITELLI, A., & NAVARRO, M. (2005) · Alcohol and Alcoholism · doi:10.1093/alcalc/agh110 · Cited by 407
Ross, R. A., Brockie, H. C., Stevenson, L. A., Murphy, V. L., Templeton, F., Makriyannis, A., & Pertwee, R. G. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702351 · Cited by 404
Early phytocannabinoid chemistry to endocannabinoids and beyond
Mechoulam, R., Hanuš, L. O., Pertwee, R., & Howlett, A. C. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3811 · Cited by 393
Evidence for novel cannabinoid receptors
BEGG, M., PACHER, P., BATKAI, S., OSEIHYIAMAN, D., OFFERTALER, L., MO, F., LIU, J., & KUNOS, G. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.11.005 · Cited by 385
Hillard, C. J., Manna, S., Greenberg, M. J., DiCamelli, R., Ross, R. A., Stevenson, L. A., Murphy, V., Pertwee, R. G., & Campbell, W. B. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38289-8 · Cited by 374
Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease
Kendall, D. A., & Yudowski, G. A. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00294 · Cited by 359
The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications
Lambert, D. M., & Fowler, C. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058183t · Cited by 350
Jbilo, O., Ravinet‐Trillou, C., Arnone, M., Buisson, I., Bribes, E., Péleraux, A., Pénarier, G., Soubrié, P., Le Fur, G., Galiègue, S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-3177fje · Cited by 346
Self-citationFunctional CB1 cannabinoid receptors in human vascular endothelial cells
Liu, J., Gao, B., Mirshahi, F., Sanyal, A. J., Khanolkar, A. D., Makriyannis, A., & Kunos, G. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3460835 · Cited by 333
Regulation of Extracellular Signal-Regulated Kinase by Cannabinoids in Hippocampus
Derkinderen, P., Valjent, E., Toutant, M., Corvol, J.-C., Enslen, H., Ledent, C., Trzaskos, J., Caboche, J., & Girault, J.-A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02371.2003 · Cited by 331
Signal transduction of the CB1 cannabinoid receptor
Turu, G., & Hunyady, L. (2010) · Journal of Molecular Endocrinology · doi:10.1677/jme-08-0190 · Cited by 325
Kim, J., Isokawa, M., Ledent, C., & Alger, B. E. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-23-10182.2002 · Cited by 318
Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond
Pertwee, R. G. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00108.x · Cited by 314
WRIGHT, K., ROONEY, N., FEENEY, M., TATE, J., ROBERTSON, D., WELHAM, M., & WARD, S. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.026 · Cited by 299
Agonist Selective Regulation of G Proteins by Cannabinoid CB1 and CB2 Receptors
Glass, M., & Northup, J. K. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12404-2 · Cited by 298
CB1 Cannabinoid Receptors and their Associated Proteins
Howlett, A., Blume, L., & Dalton, G. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790980023 · Cited by 295
Auclair, N., Otani, S., Soubrie, P., & Crepel, F. (2000) · Journal of Neurophysiology · doi:10.1152/jn.2000.83.6.3287 · Cited by 290
Cannabinoid receptors and the regulation of immune response
Berdyshev, E. V. (2000) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(00)00195-x · Cited by 280
Expression of Cannabinoid CB1 Receptors by Vagal Afferent Neurons Is Inhibited by Cholecystokinin
Burdyga, G., Lal, S., Varro, A., Dimaline, R., Thompson, D. G., & Dockray, G. J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5404-03.2004 · Cited by 280
Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., Vogt, L. J., & Sim‐Selley, L. J. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0732447.x · Cited by 273
The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt
del Pulgar, T. G., Velasco, G., & Guzmán, M. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3470369 · Cited by 259
Hillard, C. J. (2000) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(00)00051-4 · Cited by 254
Ross, R. A., Coutts, A. A., McFarlane, S. M., Anavi-Goffer, S., Irving, A. J., Pertwee, R. G., MacEwan, D. J., & Scott, R. H. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(00)00135-0 · Cited by 172
Lee, S.-H., Ledri, M., Toth, B., Marchionni, I., Henstridge, C. M., Dudok, B., Kenesei, K., Barna, L., Szabo, S. I., Renkecz, T., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4112-14.2015 · Cited by 133
“In addition, compelling evidence based on inverse CB1 agonists used in expression systems (Bouaboula et al., 1997; Pan et al., 1998) and in brain tissue (Mato et al.”
BackgroundIn vivo characterization of high Basal signaling from the ghrelin receptor
Petersen, P. S., Woldbye, D. P. D., Madsen, A. N., Egerod, K. L., Jin, C., Lang, M., Rasmussen, M., Beck-Sickinger, A. G., & Holst, B. (2009) · Endocrinology · doi:10.1210/en.2008-1638 · Cited by 121
Cannabinoids modulate pain by multiple mechanisms of action
Richardson, J. D. (2000) · The Journal of Pain · doi:10.1016/s1526-5900(00)90082-8 · Cited by 109
McMahon, L. R., & Koek, W. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.04.054 · Cited by 57
“If such limitations are related to inhibition of endogenous tone or to inverse agonist activity at cannabinoid CB1 receptors (Bouaboula et al., 1997), then other cannabinoid CB1 receptor inverse agonists should be similarly limited in their cannabinoid antagonist activity.”
BackgroundCannabinoid receptor systems: therapeutic targets for tumour intervention.
Jones, S., & Howl, J. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.6.749 · Cited by 13
“However, both are reported to demonstrate properties of inverse agonism [36].”
Background
Metadata
- Authors
- Bouaboula, M., Perrachon, S., Milligan, L., Canat, X., Rinaldi-Carmona, M., Portier, M., Barth, F., Calandra, B., Pecceu, F., Lupker, J., Maffrand, J.-P., Le Fur, G., & Casellas, P.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1997-08
- Volume
- 272
- Issue
- 35
- Pages
- 22330-22339
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2127160263
- Cited by
- 461
- References
- 52
- FWCI
- 22.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.